When will the therapy be available for patients?
The clinical trial presented above represents an initial safety and efficacy trial in chronically infected hepatitis B patients. If this trial is successful, further clinical phase II and III trials have to follow to complete the clinical development. This is requested routinely for all new medical treatments before they can be approved for routine clinical use.
If TherVacB is efficient and passes all clinical trials and will have proven its capacity to cure HBV, a product launch is expected around 2028.